CoChat
Sign Up
Cited by 997

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Tang, Weiwei, Chen, Ziyi, Zhang, Wenling, Cheng, Ye, Zhang, Betty, Wu, Fan, Wang, Qian, Wang, Shouju, Rong, Dawei, Reiter, F. P., De Toni, E. N., Wang, Xuehao·2020·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-020-0187-xPMC PMC7292831
Open this paper in CoChat — free account

Abstract

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafenib is becoming increasingly common. This study aims to identify factors contributing to resistance and ways to mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated cell death, and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-0187-x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Molecular mechanisms by which lncRNAs and miRNAs modulate sorafenib resistance. a LncRNAs can act as a “sponge” of miRNAs, competitively binding miRNAs, and thus affect the regulation of miRNAs on downstream target genes. The figure lists the lncRNAs and corresponding sponged miRNAs associated with SR. b As a scaffold or bridge for protein interaction, lncRNAs affect the formation of protein multimers and regulate protein activity. c As an RNA decoy, lncRNAs bind to transcription factors and interfere with their binding to the gene promoter region, thereby regulating transcription. d LncRNAs recruit chromatin modifiers to alter the level of chromatin modification, thereby affecting gene transcription and expression. e LncRNAs bind to mRNA and inhibit translation. f MiRNAs have the ability to degrade mRNA and prevent mRNA translation. The figure lists the miRNAs associated with SR. Note: A pentagram indicates no relative report with SR in HCC
Fig. 1 Molecular mechanisms by which lncRNAs and miRNAs modulate sorafenib resistance. a LncRNAs can act as a “sponge” of miRNAs, competitively binding miRNAs, and thus affect the regulation of miRNAs on downstream target genes. The figure lists the lncRNAs and corresponding sponged miRNAs associated with SR. b As a scaffold or bridge for protein interaction, lncRNAs affect the formation of protein multimers and regulate protein activity. c As an RNA decoy, lncRNAs bind to transcription factors and interfere with their binding to the gene promoter region, thereby regulating transcription. d LncRNAs recruit chromatin modifiers to alter the level of chromatin modification, thereby affecting gene transcription and expression. e LncRNAs bind to mRNA and inhibit translation. f MiRNAs have the ability to degrade mRNA and prevent mRNA translation. The figure lists the miRNAs associated with SR. Note: A pentagram indicates no relative report with SR in HCCCC BY · PubMed Central
Fig. 2 Exosome application in HCC therapy. Exosomes derived from cancer cells can be used to deliver functional RNAs, including lncRNAs, siRNAs, miRNAs, and mRNAs
Fig. 2 Exosome application in HCC therapy. Exosomes derived from cancer cells can be used to deliver functional RNAs, including lncRNAs, siRNAs, miRNAs, and mRNAsCC BY · PubMed Central
Fig. 3 Schematic diagram of autophagy flux. Autophagy is initiated (primed) by the nucleation of a membrane or phage. This process is initiated by the ULK1-Atg13-FIP200 complex. The membrane is then elongated to engulf the cytoplasmic component (elongation). The elongation of the phagocytic membrane depends on the Atg5-Atg12-Atg16 and LC3 coupling systems. At a later stage of autophagosome formation, LC3-II is localized to the elongated barrier membrane, while the Atg5-Atg12-Atg16 complex dissociates therefrom. Finally, the barrier membrane is closed to form autophagosomes. After autophagosome formation, lysosomes fuse with autophagosomes to form autolysosomes (autophagosome–lysosome fusions). The lysosomal hydrolase degrades the content (degradation) in the autophagosome. Beclin 1-VPS34-UVRAG complex positively regulates fusion and degradation
Fig. 3 Schematic diagram of autophagy flux. Autophagy is initiated (primed) by the nucleation of a membrane or phage. This process is initiated by the ULK1-Atg13-FIP200 complex. The membrane is then elongated to engulf the cytoplasmic component (elongation). The elongation of the phagocytic membrane depends on the Atg5-Atg12-Atg16 and LC3 coupling systems. At a later stage of autophagosome formation, LC3-II is localized to the elongated barrier membrane, while the Atg5-Atg12-Atg16 complex dissociates therefrom. Finally, the barrier membrane is closed to form autophagosomes. After autophagosome formation, lysosomes fuse with autophagosomes to form autolysosomes (autophagosome–lysosome fusions). The lysosomal hydrolase degrades the content (degradation) in the autophagosome. Beclin 1-VPS34-UVRAG complex positively regulates fusion and degradationCC BY · PubMed Central
Fig. 4 The mechanisms of ferroptosis and sorafenib resistance. The key factor leading to ferroptosis are ROS, which are produced by iron accumulation and lipid peroxidation. This figure shows the relevant pathways that regulate iron and lipid peroxidation. SLC3A2 solute carrier family 3 member 2, SLC7A11 solute carrier family 7 member 11, BSO L-buthionine-sulfoximine, GPX4 glutathione peroxidase 4, PUFA polyunsaturated fatty acids, LOX lipoxygenase, NCOA4 nuclear receptor coactivator 4, PHKG2 phosphorylase kinase G2, HSPB1 heat shock protein family B (small) member 1, IREB2 iron-responsive element-binding protein 2
Fig. 4 The mechanisms of ferroptosis and sorafenib resistance. The key factor leading to ferroptosis are ROS, which are produced by iron accumulation and lipid peroxidation. This figure shows the relevant pathways that regulate iron and lipid peroxidation. SLC3A2 solute carrier family 3 member 2, SLC7A11 solute carrier family 7 member 11, BSO L-buthionine-sulfoximine, GPX4 glutathione peroxidase 4, PUFA polyunsaturated fatty acids, LOX lipoxygenase, NCOA4 nuclear receptor coactivator 4, PHKG2 phosphorylase kinase G2, HSPB1 heat shock protein family B (small) member 1, IREB2 iron-responsive element-binding protein 2CC BY · PubMed Central
Fig. 5 Hypoxia-related sorafenib resistance mechanisms and strategies for targeting HIFs. Sustained sorafenib treatment enhances hypoxia-inducible factors 1 alpha and 2 alpha, thereby promoting transcription of multiple genes involved in proliferation, glucose metabolism, angiogenesis, and different pathways, leading to sorafenib resistance. This resistance can be overcome by different small molecules or drugs inhibiting HIFs
Fig. 5 Hypoxia-related sorafenib resistance mechanisms and strategies for targeting HIFs. Sustained sorafenib treatment enhances hypoxia-inducible factors 1 alpha and 2 alpha, thereby promoting transcription of multiple genes involved in proliferation, glucose metabolism, angiogenesis, and different pathways, leading to sorafenib resistance. This resistance can be overcome by different small molecules or drugs inhibiting HIFsCC BY · PubMed Central
Fig. 6 Schematic diagram of the sorafenib resistance-mediated immune mechanism. CD8+ CTL cells, NK cells, DC cells, and macrophages have been confirmed to be involved in sorafenib resistance through different mechanisms
Fig. 6 Schematic diagram of the sorafenib resistance-mediated immune mechanism. CD8+ CTL cells, NK cells, DC cells, and macrophages have been confirmed to be involved in sorafenib resistance through different mechanismsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 170

  1. Torre, L. A. et al. Global cancer statistics, 2012. Cancer J. Clin.65, 87–108 (2015). · DOI
  2. Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim.2, 16018 (2016). · DOI · Paper page
  3. Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet391, 1301–1314 (2018). · DOI
  4. Li, L. & Wang, H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett.379, 191–197 (2016). · DOI
  5. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–109 (2004). · DOI
  6. Vogel, A. & Saborowski, A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat. Rev.82, 101946 (2020). · DOI
  7. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo controlled trial. Lancet Oncol.10, 25–34 (2009). · DOI · Paper page
  8. Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet391, 1163–117 (2018). · DOI · Paper page
  9. Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet389, 56–66 (2017). · DOI
  10. Zhu, A. X. et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol.16, 859–870 (2015). · DOI
  11. Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med.379, 54–63 (2018). · DOI
  12. Liu, X. & Qin, S. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges. Oncologist24, S3–S10 (2019). · DOI
  13. Trojan, J. & Waidmann, O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J. Hepatocell. Carcinoma3, 31–36 (2016). · DOI
  14. Cheng, A. L. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann. Oncol.30, ix186–ix187 (2019). · DOI
  15. Sui, Z. G. et al. Sorafenib plus capecitabine for patients with advanced hepatocellular caicinoma. China Pharm.19, 848–849 (2008).
  16. Colagrande, S. et al. Advanced hepatocellular carcinoma and sorafenib: diagnosis, indications, clinical and radiological follow-up. World J. Hepatol.7, 1041–1053 (2015). · DOI
  17. Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann. Oncol.31, 470–479 (2020). · DOI
  18. Li, S. et al. Epigenetics/Epigenomics of triterpenoids in cancer prevention and in health. Biochem. Pharmacol.175, 113890 (2020). · DOI
  19. Baharudin, R. et al. Epigenetics of SFRP1: the dual roles in human cancers. Cancers12, 445 (2020). · DOI
  20. Li, W. et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res.38, 183 (2019). · DOI
  21. Chen, S. & Xia, X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J. Cell. Physiol.234, 14999–15009 (2019). · DOI
  22. Schultheiss, C. S. et al. The long non-coding RNA H19 suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma. Cell Stress1, 37–54 (2017). · DOI
  23. Jin, W. et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol. Rep.37, 273–280 (2017). · DOI
  24. Tang, S. et al. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Oncotarget7, 73257–73269 (2016). · DOI
  25. Takahashi, K. et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio4, 458–467 (2014). · DOI · Paper page
  26. Quagliata, L. et al. High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Lab. Invest.98, 95–105 (2018). · DOI
  27. Zhang, T. et al. SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumour Biol.37, 2379–2385 (2016). · DOI
  28. Ye, J. et al. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p. Onco Targets Ther.12, 415–422 (2019). · DOI
  29. Sui, C. et al. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. J. Cell Mol. Med.23, 6024–6033 (2019). · DOI
  30. Wang, Z. et al. Anti-GPC3 antibody tagged cationic switchable lipid-based nanoparticles for the co-delivery of anti-miRNA27a and sorafenib in liver cancers. Pharm. Res.36, 145 (2019). · DOI
  31. Zhang, M et al. MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. Am. J. Cancer Res.9, 765–778 (2019).
  32. Jiang, X. M. et al. MicroRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. Biomed. Pharmacother.105, 1147–1154 (2018). · DOI
  33. Callegari, E. et al. MiR-199a-3p modulates MTOR and PAK4 pathways and inhibits tumor growth in a hepatocellular carcinoma transgenic mouse model. Mol. Ther. Nucleic Acids11, 485–493 (2018). · DOI
  34. Pollutri, D. et al. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis.9, 4 (2018). · DOI
  35. Lu, A. Q. et al. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. Oncol. Rep.37, 2071–2078 (2017). · DOI
  36. Fornari, F. et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3-mediated apoptosis. Clin. Cancer Res.23, 3953–3965 (2017). · DOI
  37. Potenza, N. et al. MicroRNA-125a-5p Is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells. J. Cell Physiol.232, 1907–1913 (2017). · DOI
  38. Xu, J. et al. The miR-367-3p increases sorafenib chemotherapy efficacy to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals. EBioMedicine12, 55–67 (2016). · DOI
  39. Azumi, J. et al. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Cancer Sci.107, 1256–1262 (2016). · DOI
  40. Lou, G. et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol.8, 122 (2015). · DOI · Paper page
  41. Wang, H. et al. MicroRNA-591 functions as a tumor suppressor in hepatocellular carcinoma by lowering drug resistance through inhibition of far-upstream element-binding protein 2-mediated phosphoinositide 3-Kinase/Akt/mammalian target of rapamycin axis. Pharmacology104, 173–186 (2019). · DOI
  42. Dietrich, P. et al. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut67, 1328–1341 (2018). · DOI
  43. Kabir, T. D. et al. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology67, 216–231 (2018). · DOI
  44. Mendez-Blanco, C. et al. Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells. Cancers11, 1984 (2019). · DOI
  45. Wong, T. L. et al. CRAF methylation by PRMT6 regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. Hepatology71, 1279–1296 (2019). · DOI
  46. Fan, Z. et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cancer Lett.450, 132–143 (2019). · DOI
  47. Gailhouste, L. et al. Differentiation therapy by epigenetic reconditioning exerts antitumor effects on liver cancer cells. Mol. Ther.26, 1840–1854 (2018). · DOI
  48. Wang, T. et al. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells. Cell Death Differ.25, 2086–2100 (2018). · DOI
  49. Liu, Y. et al. Demethylation-induced overexpression of Shc3 drives c-Raf-independent activation of MEK/ERK in HCC. Cancer Res.78, 2219–2232 (2018). · DOI
  50. Liu, J. et al. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol. Rep.38, 899–907 (2017). · DOI
  51. Abeni, E. et al. Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. Int. J. Oncol.51, 128–144 (2017). · DOI
  52. Huo, Q. et al. Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell Death Dis.8, e2766 (2017). · DOI
  53. He, R. Z., Luo, D. X. & Mo, Y. Y. Emerging roles of lncRNAs in the post-transcriptional regulation in cancer. Genes Dis.6, 6–15 (2019). · DOI
  54. Lee, D. D. et al. DNA methylation of the TERT promoter and its impact on human cancer. Curr. Opin. Genet. Dev.60, 17–24 (2020). · DOI
  55. Hudlikar, R. R. et al. Triterpenoid corosolic acid modulates global CpG methylation and transcriptome of tumor promotor TPA induced mouse epidermal JB6 P+ cells. Chem. Biol. Interact.321, 109025 (2020). · DOI
  56. Mancini, M. et al. HP1s modulate the S-adenosyl methionine pathway in liver cancer cells. Biochem J.477, 1033–1047 (2020). · DOI
  57. Beretta, G. L. et al. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem.142, 271–289 (2017). · DOI
  58. Durmus, S., Hendrikx, J. J. & Schinkel, A. H. Apical ABC transporters and cancer chemotherapeutic drug disposition. Adv. Cancer Res.125, 1–41 (2015). · DOI
  59. Arrighetti, N. et al. Exosome-like nanovectors for drug delivery in cancer. Curr. Med. Chem.26, 6132–6148 (2019). · DOI
  60. Gowda, R. et al. The role of exosomes in metastasis and progression of melanoma. Cancer Treat. Rev.85, 101975 (2020). · DOI
  61. Di Giacomo, S. et al. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch. Toxicol.93, 623–634 (2019). · DOI
  62. Wang, H. et al. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. Mol. Med Rep.12, 3902–3908 (2015). · DOI
  63. Chow, A. K. et al. The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS ONE8, e78675 (2013). · DOI
  64. Wang, G. et al. Exosomal MiR-744 inhibits proliferation and sorafenib chemoresistance in hepatocellular carcinoma by targeting PAX2. Med. Sci. Monit.25, 7209–7217 (2019). · DOI
  65. Qu, Z. et al. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J. Exp. Clin. Cancer Res.35, 159 (2016). · DOI
  66. Takahashi, K. et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol. Cancer Res.12, 1377–1387 (2014). · DOI · Paper page
  67. Li, H et al. Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma. J. Nanobiotechnol.16, 103 (2018). · DOI
  68. Shi, S. et al. Dendritic cells pulsed with exosomes in combination with PD-1 antibody increase the efficacy of sorafenib in hepatocellular carcinoma model. Transl. Oncol.11, 250–258 (2018). · DOI
  69. Jayaseelan, V. P. Emerging role of exosomes as promising diagnostic tool for cancer. Cancer Gene Ther. (2019). · DOI
  70. Tian, W., Liu, S. & Li, B. Potential role of exosomes in cancer metastasis. Biomed. Res. Int.2019, 4649705 (2019).
  71. Safaei, R. et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther.4, 1595–604 (2005). · DOI
  72. Lee, Y. & Overholtzer, M. After-death functions of cell death. Yale J. Biol. Med.92, 687–694 (2019).
  73. Galimov, E. R., Lohr, J. N. & Gems, D. When and how can death be an adaptation? Biochemistry84, 1433–1437 (2019).
  74. Shi, Y. H. et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy7, 1159–1172 (2011). · DOI
  75. Zhai, B. et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol. Cancer Ther.13, 1589–1598 (2014). · DOI
  76. Yuan, H. et al. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J. Gastroenterol.20, 4953–4962 (2014). · DOI
  77. Ling, S. et al. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. Int. J. Oncol.50, 297–309 (2017). · DOI
  78. Luo, T. et al. PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression. Autophagy12, 1355–1371 (2016). · DOI
  79. Fischer, T. D. et al. Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. World J. Hepatol.6, 752–758 (2014). · DOI
  80. Wu, F. Q. et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. J. Hepatol.65, 314–324 (2016). · DOI
  81. Yu., S. et al. B-cell lymphoma-2-associated transcription factor 1 is overexpressed and contributes to sorafenib resistance in hepatocellular carcinoma. Hepatol. Res.49, 1329–1340 (2019). · DOI
  82. Dai, N. et al. Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling. Oncol. Rep.40, 3235–3248 (2018).
  83. Lu, S. et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis.9, 646 (2018). · DOI
  84. He, C. et al. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget6, 28867–28881 (2015). · DOI
  85. Stiuso, P. et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol. Ther. Nucleic Acids4, e233 (2015). · DOI
  86. Dai, E. et al. AIFM2 blocks ferroptosis independent of ubiquinol metabolism. Biochem. Biophys. Res. Commun.523, 966–971 (2020). · DOI
  87. Zhang, Z. et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy 1–24 (2019). · DOI
  88. Sun, X. et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology64, 488–500 (2016). · DOI
  89. Zhang, Z. et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy14, 2083–2103 (2018). · DOI
  90. Janku, F. et al. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol.8, 528–539 (2011). · DOI
  91. Mizushima, N. Autophagy: process and function. Genes Dev.21, 2861–73 (2007). · DOI
  92. Shintani, T. & Klionsky, D. J. Autophagy in health and disease: a double-edged sword. Science306, 990–995 (2004). · DOI
  93. White, E. & DiPaola, R. S. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res.15, 5308–5316 (2009). · DOI
  94. Liu, J. et al. Autophagy, a double-edged sword in anti-angiogenesis therapy. Med. Oncol.33, 10 (2016). · DOI
  95. Thorburn, A. Autophagy and its effects: making sense of double-edged swords. PLoS Biol.12, e1001967 (2014). · DOI
  96. Nie, J. et al. Role of ferroptosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.144, 2329–2337 (2018). · DOI
  97. Louandre, C. et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer133, 1732–1742 (2013). · DOI · Paper page
  98. Lachaier, E. et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res.34, 6417–6422 (2014).
  99. Liang, Y. et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology57, 1847–1857 (2013). · DOI
  100. Prieto-Domínguez, N. et al. Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy. Oncotarget8, 91402–91414 (2017). · DOI
  101. Xu, H. et al. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS ONE9, e115565 (2014). · DOI
  102. Li, S. et al. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death. Br. J. Cancer117, 1518–1528 (2017). · DOI
  103. Liu, F. et al. Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma. Oncol. Lett.10, 778–784 (2015). · DOI
  104. Ma, L. et al. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett.355, 96–105 (2014). · DOI
  105. Zhao, D. et al. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell Signal26, 1030–1039 (2014). · DOI
  106. Xu, J. et al. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis.8, e3095 (2017). · DOI
  107. Casadei Gardini, A. et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale. Eur. J. Cancer86, 106–114 (2017). · DOI
  108. Song, Z. et al. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Cancer Lett.460, 96–107 (2019). · DOI
  109. Long, Q. et al. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun.513, 642–650 (2019). · DOI
  110. Fu, Q. H. et al. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. Tumour Biol.37, 7277–7286 (2016). · DOI
  111. Yao, W. et al. A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. EBioMedicine22, 58–67 (2017). · DOI
  112. Chen, Y. et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology61, 1591–602 (2015). · DOI · Paper page
  113. Dong, N. et al. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br. J. Cancer121, 22–33 (2019). · DOI
  114. Zhou, S. L. et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology150, 1646–1658 (2016). · DOI
  115. Chen, J. et al. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. Oncotarget7, 41274–41284 (2016). · DOI
  116. Li, C. et al. Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2. Int. Immunopharmacol.76, 105855 (2019). · DOI
  117. Tao, Z. et al. Targeting the YB-1/PD-L1 axis to enhance chemotherapy and antitumor immunity. Cancer Immunol. Res.7, 1135–1147 (2019). · DOI
  118. Lin, X. et al. Silencing MYH9 blocks HBx-induced GSK3beta ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct. Target Ther.5, 13 (2020). · DOI
  119. Witt-Kehati, D. Inhibition of pMAPK14 overcomes resistance to sorafenib in hepatoma cells with hepatitis B. Virus11, 511–517 (2018).
  120. Ching, R. H. H. et al. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. Oncotarget8, 23507–23516 (2017). · DOI
  121. Liu, L. P. et al. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin. Cancer Res.18, 5662–5671 (2012). · DOI
  122. Xu, M. et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radio.54, 199–204 (2013). · DOI
  123. Xu, M. et al. Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol.33, 275–281 (2014). · DOI
  124. Yeh, C. C. et al. Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer. Mol. Cell Proteom.14, 1527–1545 (2015). · DOI
  125. Méndez-Blanco, C. et al. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp. Mol. Med50, 134 (2018). · DOI
  126. Nakamura, K. & Smyth, M. J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell. Mol. Immunol.17, 1–2 (2019). · DOI
  127. Zhu, H. et al. Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: a case report. Medicine98, e15755 (2019). · DOI
  128. Berasain, C. et al. Inflammation and liver cancer: new molecular links. Ann. N. Y. Acad. Sci.1155, 206–221 (2009). · DOI
  129. Pattullo, V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression—prevention is better than cure. World J. Hepatol.7, 954–967 (2015). · DOI
  130. D’Angelo, S. et al. Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma? World J. Gastroenterol.19, 2141–2143 (2013). · DOI
  131. Zuo, C. et al. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection. Oncol. Lett.9, 527–534 (2015). · DOI
  132. Descamps, V. et al. The kinase-inhibitor sorafenib inhibits multiple steps of the hepatitis C virus infectious cycle in vitro. Antivir. Res.118, 93–102 (2015). · DOI
  133. Cabrera, R. et al. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharm. Ther.37, 91–97 (2013). · DOI
  134. Himmelsbach, K. & Hildt, E. The kinase inhibitor sorafenib impairs the antiviral effect of interferon alpha on hepatitis C virus replication. Eur. J. Cell Biol.92, 12–20 (2013). · DOI
  135. Zhang, Q. B. et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS ONE8, e55945 (2013). · DOI
  136. Hu, B. et al. KPNA3 confers sorafenib resistance to advanced hepatocellular carcinoma via TWIST regulated epithelial–mesenchymal transition. J. Cancer10, 3914–3925 (2019). · DOI
  137. Xu, Y. et al. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. Cancer Lett.454, 78–89 (2019). · DOI
  138. Wu, C. X. et al. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics8, 3737–3750 (2018). · DOI
  139. Tan, W. et al. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine40, 446–456 (2019). · DOI
  140. Wang, J. et al. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Lett.444, 82–93 (2019). · DOI
  141. Zhang, Y. et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis.9, 743 (2018). · DOI
  142. Fan, Z. et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cancer Lett.450, 132–143 (2019). · DOI
  143. Xiao, Y. et al. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the sorafenib therapy under hypoxia via increasing cancer stem cells phenotype. Cancer Lett.444, 175–187 (2019). · DOI
  144. Haga, Y. et al. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. PLoS ONE12, e0174153 (2017). · DOI
  145. Hagiwara, S. et al. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br. J. Cancer106, 1997–2003 (2012). · DOI
  146. Kang, D. et al. Down-regulation of TGF-beta expression sensitizes the resistance of hepatocellular carcinoma cells to sorafenib. Yonsei Med. J.58, 899–909 (2017). · DOI
  147. Wang, Z. et al. Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2. Neoplasma62, 172–179 (2015). · DOI
  148. Abou-Alfa, G. K. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA304, 2154–2160 (2010). · DOI
  149. Yang, T. et al. Ultrasound-triggered nanodroplets for targeted co-delivery of sorafenib/doxorubicin for hepatocellular carcinoma therapy. J. Biomed. Nanotechnol.15, 1881–1896 (2019). · DOI
  150. Liu, Y. et al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int. J. Clin. Oncol.20, 952–9 (2015). · DOI
  151. Ma, X. et al. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. Cell Death Dis.11, 174 (2020). · DOI
  152. Ng, L. et al. Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3beta/beta-catenin pathway. BMC Cancer18, 621 (2018). · DOI
  153. Xue, F. et al. eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma. Am. J. Transl. Res.8, 4670–4681 (2016).
  154. Chen, W. et al. Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells. Cancer Biol. Ther.15, 992–999 (2014). · DOI
  155. Geng, J. et al. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. Technol. Cancer Res. Treat.13, 377–385 (2014). · DOI
  156. Zhu, A. X. et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer110, 581–589 (2007). · DOI
  157. Sanoff, H. K. et al. PhaseII study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest. Cancer Res.4, 78–83 (2011).
  158. Asnacios, A. et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer112, 2733–2739 (2008). · DOI
  159. Zhu, A. X. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.33, 559–566 (2015). · DOI
  160. Zhu, Y. J. et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharm. Sin.38, 614–622 (2017). · DOI
  161. Zhang, H. et al. Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol. Lett.15, 9377–9384 (2018).
  162. Ye, L. et al. The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Discov.5, 86 (2019). · DOI
  163. Bollard, J. et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut66, 1286–1296 (2017). · DOI
  164. Reiter, F. P. et al. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cell. Oncol.42, 705–715 (2019). · DOI
  165. Marozin, S. et al. STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma. Cancer Gene Ther.22, 317–325 (2015). · DOI
  166. Gedaly, R. et al. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J. Surg. Res.176, 542–548 (2012). · DOI
  167. Koeberle, D. et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann. Oncol.27, 856–861 (2016). · DOI
  168. Hato, T. et al. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology60, 1776–1782 (2014). · DOI
  169. Wang, Y. et al. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. Tumour Biol.36, 1561–1566 (2015). · DOI
  170. Lo, J. et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology62, 534–545 (2015). · DOI

Cited by

Sorted by citations

See all 997

Metadata

Authors
Tang, W., Chen, Z., Zhang, W., Cheng, Y., Zhang, B., Wu, F., Wang, Q., Wang, S., Rong, D., Reiter, F. P., De Toni, E. N., & Wang, X.
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2020-06-10
Volume
5
Issue
1
ISSN
2059-3635
DOI
10.1038/s41392-020-0187-x
PMC
PMC7292831
Cited by
997
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review